NMN

Research Papers and Clinical Trials

The current evidence base for nicotinamide mononucleotide (NMN) consists primarily of preclinical animal studies and small human trials, with limited published results from controlled clinical research.

Preclinical Research

Several recent animal studies have investigated NMN's potential therapeutic effects across different conditions. A 2026 mouse study examined combination therapy with NMN and elamipretide for brain injury, focusing on TREM2 pathways, though specific outcomes were not detailed in the available evidence. Another 2026 study explored NMN's effects on heart muscle cells exposed to high glucose and fat conditions, suggesting potential benefits through SIRT1-mediated mechanisms, but sample sizes and statistical significance were not reported.

Additional preclinical work has investigated NMN in the context of bone repair and aging, with one study developing a scaffold delivery system to restore NAD+ levels in aged bone tissue. Research has also examined NMN's potential role in sperm motility when combined with acacetin, though detailed methodology and outcomes are not available from the current evidence.

Human Clinical Trials

The clinical trial landscape for NMN remains limited. One completed study (NCT04571008) examined NMN supplementation effects on organ system biology, but results have not been published or made available in the provided evidence. Several other trials are listed with unknown status, including studies on ovarian function (NCT05485610) and immune cell rejuvenation (NCT05984550, NCT06036355).

Evidence Limitations

The available evidence has significant gaps. Most studies lack detailed methodology, sample sizes, dosing information, or published results. The preclinical research, while suggestive of potential benefits across multiple organ systems, does not provide sufficient data to assess clinical relevance or safety profiles. The human trials either lack published results or have unclear completion status.

This information is for research purposes only and should not be considered medical advice. Consult healthcare providers before considering any experimental treatments.